VER
Vascular & Endovascular Review

RESEARCH ARTICLE

Current Trends in Vascular Graft Innovation: Biocompatibility, Longevity, and Clinical Applications

Anneliese Krause

Institute of Theoretical Physics, University of Heidelberg, Germany.

Abstract

Vascular grafts constitute an essential component in the treatment of vascular disorders and injuries, and new improvements have shifted the focus on the construction and performance of such devices. Vascular grafts incorporated in this review include bioengineered and tissue-engineered grafts, new advanced materials, drug-coated systems and smart technologies. Recent development and advancement areas like decellularized scaffolds, cell-seeded constructs, and 3D bioprinting improve biocompatibility and reconstruction of tissue. Electrospun nanofibers composite polymers and biodegradable scaffolds possess better mechanical characteristics and applicability. Drug-releasing vascular grafts and smart, responsive systems associated with biosensors help deliver site-specific therapy and continuously monitor graft function. Efforts to overcome issues related to small-diameter grafts and the shift toward developing patient-customized solutions are also emerging. These trends are backed by enhancements in regulations and the joining of efforts of professionals from different fields to bring these new graft technologies into the clinics. Introducing bio-, material and technoscientific advancements into vascular grafts, the method is gradually becoming progressively efficient, long-lasting, and personalized, a significant advancement in vascular disease therapy. These advanced techniques are detailed in this review, emphasizing their promising benefits for patients and recognizing the prospects that are prominent aspects of vascular surgeons.

Keywords

Trends (TT), Vascular Graft Innovation (VGI), Biocompatibility (BC), Longevity (LL), Clinical Applications (CA)

Disclosure: The authors have no conflicts of interest to declare.

Received: 12 August 2024 **Accepted:** 3 December 2024 **Citation:** *Vascular & Endovascular Review* 2025;8: e02. **DOI:** https://doi.org/10.15420/ver.2025.08.01.02

Correspondence: Anneliese Krause, Institute of Theoretical Physics, University of Heidelberg, Germany. Email: anneliese_krause@outlook.com

The vascular graft can be explained as “a special type of medical device which can be used to replace or repair damaged blood vessels ". It has been seen that these grafts are usually made from various types of synthetic materials, such as polyester. Sometimes, natural tissues are also used to make vascular grafts, and these living tissues can also be derived from animals. There are four important types of vascular grafts, which are mostly used in healthcare sectors. These grafts are named autologous, allografts, xenografts, and synthetic grafts. If we use patients' cells to repair or replace damaged blood vessels, these grafts are named autologous grafts. If we take these tissues from any donor to replace or repair blood vessels, then these types of grafts are called allografts[1]. Sometimes, we may use animal tissues to be transplanted into human beings to treat blood vessel diseases; these types of grafts are called xenografts. Recent studies have shown that we can use synthetic materials to make grafts that can be used in the human body; these grafts are called synthetic grafts. These vascular grafts are becoming very important because of the variety of applications. For example, one of the most important applications is that these grafts are extensively used for coronary artery bypass grafting. In coronary artery bypass, when there is blockage of the coronary artery, replacement or repair of this artery can be done by using Grafts. We can also use vascular grafts in peripheral arterial disease. In peripheral Arterial Disease, there is improper blood circulation in the lower limbs because of blockage[2]. This blockage can easily be removed by using synthetic grafts. Kidney diseases are increasing day by day, and dialysis is becoming common in healthcare sectors. So, we need to create special sites for dialysis, which can also be done using grafts. However, some important complications are related to vascular grafts in the human body. The first important complication related to vascular graft is graft occlusion. When a graft is placed in the body, in some cases, blood clots are formed in that area, termed graft occlusion. The other important complication related to vascular grafts is graft infection, which is more common today. It has been seen that sometimes grafts may cause infection and can result in serious complications, termed graft

infection. In other cases, it has been seen that the immune system of the body does not accept that graft, which is termed a graft rejection. To solve all of these complications, there were some important advancements in vascular grafts, which are more useful these days[3]. The important trends related to vascular grafts are focused on enhancing biocompatibility, longevity, and other Dynamics to be improved. The biocompatibility of grafts refers to reducing the risk of graft rejection to make grafts of such materials that are acceptable to the body. Various methods can be used to enhance the biocompatibility of grafts. One of these important methods is surface modification. Sometimes, the surface of Grafts is coated with a thin layer of heparin or phosphoryl chloride, which can reduce the risk of blood clot formation at the grafting site. Some of the surfaces of vascular grafts are grafted with other biocompatible molecules, such as polyethene glycol, which will improve the biocompatibility of grafts. Recent studies have shown that if we use biodegradable materials to develop vascular grafts, these materials will also enhance the biocompatibility of grafts. Synthetic grafts have a problem because they have little extracellular matrix. We use natural materials such as collagen or elastin to form vascular grafts. In that case, these may reduce the extracellular matrix's impact, thus enhancing graft biocompatibility [4, 5]. The biocompatibility of grafts can also be improved by improving drug delivery by grafts. If we use such coatings that may release anti-inflammatory or anti-thrombotic drugs from the graft surface, there will be less risk of graft occlusion or rejection. Sometimes, there is microencapsulation of these grafts, which may also pacify the biocompatibility of these vascular grafts. The other important aspect related to current trends of vascular grafts is the longevity of these grafts. The longevity of these Graffiti can be enhanced by various methods. The first and foremost method is material selection for enhancing the longevity of vascular grafts. If we want to enhance the longevity of grafts, we must use materials with better mechanical properties. If we use such biocompatible materials, we may also improve the longevity of vascular grafts. Vascular graft design and construction are decisive factors in the longevity of vascular grafts[6]. We have to construct vascular grafts with such optimal geometry that will minimize the impact of stress on vascular grafts. We can also use reinforced materials such as woven or knitted fabrics. This aspect will enhance the mechanical strength of vascular grafts. Recent studies have shown that if we use general and specific sterilization methods to restore the mechanical properties of vascular grafts, we may improve the longevity of vascular grafts in this way. We can also use tissue engineering for the development of grafts, which uses living cells for the formation of biocompatible grafts. In recent years, there have been many problems related to constructing optimal geometry for vascular grafts[7, 8]. However, with the advancement of science and technology, this problem has also been solved by the use of 3D printing. This type of 3D printing may be helpful in customizing vascular grafts of required geometry and design. Not only are is the proper design and geometry of vascular grafts necessary,, but proper follow-up is also mandatory to monitor the functioning of these grafts in the human body[9]. There are many important clinical applications of these vascular grafts,, such as thosevascular trauma repair to open narrow or blocked blood vessels in the human body[10]. These vascular grafts have important applications in transplant surgery, where they are used to connect the blood vessels of the donor and recipient. Although there are many complications related to vascular grafts, these important advancements will pacify these complications to a great extent[11, 12].

Research Objective

The main objective of this research is to understand current trends related to vascular grafts to enhance their biocompatibility, longevity, and clinical applications. These studies have effectively explained various complications related to the use of these vascular grafts for clinical applications.

LITERATURE REVIEW

Elements involved in vascular graft innovation are 3D printing and editing of genes. One of them is tissue-engineered vascular graft, which is usually made by the implantation of scaffolding of biodegradable material, which is usually connected with the cells from the patient's bone marrow. There is a disappearing of scaffold normally. A vessel will be left behind, which will show a growth with the patient. The application of 3D printing technology can be seen while designing vascular grafts. The editing of genes is another aspect[13]. The tools of gene editing like CRISPR/Cas9 can change the material of cells, which is genetic, and its applications can be seen in the TEVGs. It can improve certain capabilities of the cells. These abilities can be anti-inflammatory, anti-thrombogenic, and endothelialization[14]. Certain other characteristics can be textile technologies. Certain things involved in textile technologies are weaving, knitting, and braiding which can create a variety of 2D and 3D structures and usually bear different mechanical properties. Some other innovations can be involved in the vascular graft here. One of them is the reprocessed natural tissue, which is considered a very new and advanced approach to the application of vascular grafts that can reprocess the natural tissue[15]. Another analyzer that can analyze the flow of high-temperature powder. The Granudrum HT is an analyzer capable of the powder's flowability and the level of cohesion at the temperature of up to 250celcius. One another element is the portable decontamination system. One of the portable decontamination systems is the SteraPak, which can provide cordless iHP disinfection[16]. Another important factor is the automatic monitoring of the polymerization reaction. A tissue-engineered vascular graft is an element that can prove an alternative for the integration, remodeling, and repairing of all the vessels that are fixed for the host. All of these elements will appear as a good response to the stimuli, which are mechanical and biochemical. In modern times, ways of preparation for the phenomenon of tissue-engineered vascular grafts are divided into scaffold-free and scaffold-based approaches[17]. The material that is usually used in the manufacturing of vascular graft design is based on various reasons, basically due to the ease and flexibility of tailoring all those mechanical properties. In case of damage to an artery or a vein, vascular surgeons do their job with the replacement of the damaged section

with a new vessel, usually known as the graft. This graft can be synthetic or tissue in nature. Many times, it may also happen that a human blood vessel is usually generated from the donor or sometimes from any other that is found in the body of the patient. The ability of the material to function within the biological system will not become the reason for any danger or the reason for eliciting any toxic response, which will be covered under the topic of biocompatibility[18]. It will appear as the measurement of the level at which the body usually accepts a material. Biocompatibility is a factor that is of great significance for materials that are usually utilized in invasive medical devices. One of the common examples is the implants. In the case of the implantation of a material, it will become the reason of trigger for the foreign reaction of the body in the tissues within the body[19].

The extent of this reaction usually determines the level of biocompatibility. The biocompatibility evaluation is usually done with the help of a range of tests, which can be in vitro or in vivo. These tests can assess the material's chemical, mechanical, and structural properties. Its interaction with the biological environment is also observed[20]. Let's discuss certain properties which are involved in it. One of them is the chemical inertness. It is based on the type of material that can be toxic. Another thing is thromobogenicity, which elaborates that either the material can lead to blood coagulation or the formation of a thrombus. Resistance towards adhesions will become the representation of the material that either is resistant to adhesion or not[21]. Biocompatible material can be seen in various applications in which dentistry is also involved. Let's discuss these examples. These biocompatible materials can be utilized to fill the cavities and make the repairs in a method that wiusing look more natural compared to conventthanial.

All those situations are about compatibility with the tissues living in nature or with the system, which is all about living things with characteristics that are not toxic or injurious without causing any rejection, which can prove immunological[22]. In the case of a biocompatible material, nature represents that it will not cause any harmful effects when it has a connection with the body. It also proves as an elaboration that every material will have its task that will be performed by it without causing any effect that can unplanned[23]. Atherosclerosis and other diseases, which are consequential disease processes, will become the major reasons for morbidity, mortality, and expenditures, which are all about healthcare[24, 25]. Advanced therapies and medical treatments will appear as the best things that can give this permission to combat diseases effectively[26]. All the technological advances are all about the stents and surgical conduits, which will prove the advancement in the coronary artery diseases and the diseases which are all about the peripheral vascular.

Figure 1: Immune Compatibility

Immune Compatibility

Immune reactions that lead to graft rejection or inflammation present one of the greatest problems in terms of biocompatibility for the vascular grafts. Any material that elicits an immune response tends to induce chronic inflammation, fibrosis and graft failure (Figure 1). PTFE and DACRON are the most common polymers as they are biologically inactive but lack the bioactivity to fix around the tissues. In order to counter this, the use of bioengineered grafts is common and widely embraced, they include decellularized matrices and tissue-engineered constructs. These grafts are constructed from natural source tissues, which has been decellularized to remove all tissue-specific cells and their components; what remains is the acellular support tissue or extracellular matrix (ECM).

Anti-Thrombogenic Properties

Thrombosis occurs commonly within vascular grafts, particularly in small caliber grafts of diameter less than 6mm. It also requires that the blood-contacting surface of the graft remains non-thrombogenic, with no platelet adhesion and activation but at the same time should achieve hemostasis. Other methods have included the use of heparin or nitric oxide releasing compounds for the purpose of trying to reduce or prevent blood clot formation in the grafts. Use of hydrophilic polymers such as poly ethylene glycol (PEG) on the surface of the grafts removed proteins and platelets from adhering to the graft once again improving its anti-thrombogenicity.

Integration and Therapeutic

Biodegradable grafts formed of polymers like polyglycolic acid (PGA) or polylactic acid (PLA) gradually disintegrate, replacing the defected blood vessel by a newly regenerated one. Such grafts are especially applicable in the treatment of children because their natural tissues tend to grow. Electro spun nanofibers are also used in development of grafts that could replace

ECM, to support cell migration, proliferation and tissue formation.

Longevity

The shelf life is an essential factor in the success of the vascular grafts, especially for consistent patient use. Longevity deals with the maintenance of graft structure, function, and patency following a given intervention and the rarity with which the same intervention will need to be repeated. These parameters define longevity by addressing the material properties' durability, biostability, and mechanical properties, and a structural robustness opposed to most major complications of therapy such as thrombosis, infection, and intimal hyperplasia. The two most common types of synthetic grafts are PTFE and Dacron, which have proved to be mechanically stronger and more durable for larger bore vessels that require replacement. Nonetheless, their employment in the construction of small diameter stents is still somewhat restrained due to the increased incidence of occlusion, and thrombosis. Adult stem cells are tissue-engineered scaffolds and biodegradable materials for tissue repair that are gradually removed and replaced by natural tissue while creating a functional vascular network. Incorporation of newer central layers of the graft also include anti-thrombotic agents/bioactive molecules, which has helped to enhance graft life span through interposition of clot formation; besides improvement of reendothelialization.

Clinical Applications

Vascular grafts are used in virtually all spheres of clinical practice starting from arterial reconstructions up to the congenital vascular defects management. Aside from that, their main use is in coronary artery bypass grafting (CABG), which involves surgeries intended to bring blood flow to the heart back to its normalcy. In such vital uses, the achievement of high patency rates with small-diameter prostheses is mandatory. Surgical grafts include peripheral arterial disease (PAD) and hemodialysis access; however, their application in CABG is limited because they show poor patency in small vessels. The saphenous vein is still preferred in CABG; nevertheless, tissue-engineered materials are slowly finding their way as more suitable substitutes. Aside from arterial bypass, the grafts are used often in the context of trauma, aneurysms as well as AV access in patients on dialysis. In aneurysm repair, large diameter grafts are used in endovascular or open surgical operations to reconstruct the defective portion of the artery. In vascular access for dialysis, the key target is to make graft longevity and largely obviate issues such as stenosis or infection. New areas of clinical application are associated with customized grafts as bioengineered tissue substitute in pediatric patients suffering from congenital heart or vascular diseases. In such instances, grafts must support growth and therefore biodegradable or tissue-regenerative designs are particularly appropriate. In addition, progress in the field of vascular grafting has broadened their application not only in cardiovascular but also in reconstructive and plastic surgery in which micro vascular grafts enable replantation, tissue perfusion, and therapeutic of a particular injury. In conclusion, the two concepts of vascular graft longevity and its uses are two sides of the same coin, since overall performance and service of the materials is a fundamental factor that determines patient success rates through different disease affiliations. The present development in the new material, bioengineering, as well as patient-specific solutions play a vital role to further improve the performance and increase the range of the vascular grafts use in the modern medical field.

Current Trends in Vascular Graft Innovation

Vascular grafts, which are used to treat vascular diseases and injury, have received comparably enhanced advances in the recent past. This still goes on over time, with developments being made in a bid to enhance the compatibility, strength, and utility of grafts and overcome the downfalls of conventional graft materials and procedures. Key trends in vascular graft innovation include:

Bioengineered and Tissue-Engineered Grafts:

Decellularized Scaffolds: Vasculature, like veins or arteries, are harvested and subsequently confined to immunogenic elements to leave behind a matrix in which host cells may thrive and regenerate.

Cell-Seeded Grafts: These conduits with autologous or stem cells are less liable to thrombotic occlusion and provide better reendothelialization and long-term results.

3D Bioprinting: New generations of scaffolds that can be fabricated through tissue engineering contain accurate shape, structure, and biomimetic properties that can satisfy patients' specific needs.



Figure 2: Drug-Eluting Vascular Grafts

Drug-Eluting Vascular Grafts

Pharmacological properties of drug-eluting implanted in the grafts minimize chances of restenosis and thrombosis. Such prodrugs as antiplatelet, anti-inflammatory, or antiproliferative agents are incorporated into graft materials for deliberate, sustained release (Figure 2). Drug-eluting vascular grafts (DEVGs) are a contemporary technology developed as an improved system to bypass the shortcomings of bare-metal grafts while providing mechanical support and site-specific drug release. These grafts are designed to provide a sustained slow release of the agent at the affected site and are designed for tackling specific problems involving thrombus formation, re-(neointimal) hyperplasia, infection, and inflammation.

DEVGs improve graft performances, separate local and systemic drug delivery, and decrease the need for the latter because of adverse side effects usually associated with its administration. At the heart of a drug-eluting vascular graft technology is the graft structure and the capacity to load and deliver bioactive agents at precise rates. Polymeric grafts are made from synthetic plastics, such as PTFE, polyurethane, or polycaprolactone, and the graft material itself is specifically designed to contain reservoirs or surface coatings for drug incorporation. Collagen and other natural polymers are also applied because of their biocompatibility and compatibility with the vascular niche.

Medications can be incorporated into the graft through the use of the drugs being physically built right into the grafting material or through the use of certain surface coatings. Film coats in nanoparticles, microparticles or a hydrogel layer may be used to ensure prolonged and constant drug release. The release rate is controlled and optimized by altering the polymer composition, thickness of each layer, or the interaction of the drug and a carrier material. Techniques like electrospinning again allow focused incorporation of drugs within the nanofibrous scaffolds that imitate ECM and are helpful structurally and therapeutically.



Figure 3: Biodegradable Vascular Grafts

Biodegradable Vascular Grafts

Bioresorbable grafts dissolve over time while remodelling tissue at the site of grafting, thereby minimizing the likelihood of graft complications and additional operations in the future (Figure 3). Fully biodegradable vascular grafts have been born as a new concept in vascular medicine since permanent synthetic grafts present some concerns. These grafts only offer the necessary scaffolding to the vessel during the critical therapeutic period and dissolve with time, while the morphologically and functionally sound neo-vessel tissue composed of the patient's cells is formed. Such an approach avoids many complications but encourages the body's healing process, making vascular grafts biodegradable, which is a crucial breakthrough in vascular surgery. Biodegradable vascular graft and its success depends on materials selected for use, which need to be biocompatible, mechanically sound and most importantly, self-degradable in a controlled manner. Polyglycolic acid is abbreviated as PGA. Polylactic acid, abbreviated PLA.

Polycaprolactone, abbreviated as PCL. PGA degrades comparatively quickly, so it is helpful in applications such as wound therapeutic, where tissue regeneration is anticipated to be comparatively swift. Conversely, PLA has a lower degradation rate and better mechanical strength. PCL has a very low degradation rate and is very flexible, making it much slower than the above for instances where support is needed for a longer period. These polymers may be blended or altered with other materials to provide specific characteristics. Along with synthetic polymers, natural polymers, including collagen, fibrin, and silk, have attracted interest because of their bioactivity and ECM mimicry. These materials promote the adhesion, migration, and proliferation of the cells in the graft and improve its remodelling by the host cells. Current sophisticated techniques such as electrospinning and 3DBI help design grafts with nanofibrillar structures to mimic the nature of the ECM microenvironment for tissue repair.

Mechanism of Action

While the graft ensures mechanical support, cell survival issues arise when the host cells, such as endothelial and smooth muscle cells, move into the scaffold. These cells lay down ECM contents, for instance, collagen and elastin materials, gradually replacing the synthetic material. Eventually the graft disintegrates into nontoxic compounds such as carbon dioxide and water which are in any way cleared from the body. The degradation rate should closely track the tissue regeneration process, which means that the

scaffold retains its structural integrity up to the time when the vessel becomes fully autonomous.

Figure 4: Personalized Medicine in Grafts

Personalized Medicine in Grafts

Enhanced through-visualization, computational and artificial intelligence analytical studies, 3-D modeling, and printing facilitate the fabricating of grafts that appropriately match the patient's anatomy and clinical indication for a better prognosis. The enthusiasm around this scientific concept of serving every patient according to the patient's physiologic, genomic, and clinical individuality is heralding the era of the new personalized medicine (Fig 4). In the case of vascular grafts, the concept of personalized medicine is revolutionising the field and the management of cases of patients suffering from vascular diseases since it breaks the monotony of a standard treatment model. The use of enhanced imaging, computational simulations, and bioengineering has provided the basis for fabrication of vascular grafts that can be tailored to match the needs of the individual client.

Customized Design and Manufacturing

Due to the development in imaging capabilities, CT angiograms and MR angiograms have become available for a physician to obtain a clear anatomical roadmap of a patient's vascular system. This information is applied to construct vessels for implantation that have similar size, shape and branching pattern as the recipient vessels. Three-dimensional printing technologies have also enhanced the process of creating the vascular grafts because they allow rapid fabrication of complex structures and geometries that are similar to those of the natural vessels. This is demonstrated because the off-the-shelf grafts are associated with such complexities as graft migration, leakage, and mismatch.

Biocompatibility and Biomimicry

Individualized vascular grafts have a main focus on biocompatibility and the biomimetic approach so that they can be incorporated in the patient's tissues. For example, biodegradable grafts may be engineered to release itself at the pace of the body medicinal process, thus leaving behind a vascular infrastructure. Consequently, autologous cell seeded grafts, like endothelial or stem cells harvested from the patient, provide excellent immune rejection and thrombogenicity attributes and also encourage natural endothelial growth and vascular adaptation.

Genomic and Proteomic Integration

Genomic and proteomic information's incorporation into graft design is another direction in the development of personalized medicine. It is possible to distinguish individual risk indicators for the development of some states, for example, thrombosis or inflammation, to choose materials and coatings for the graft. For instance, a particular individual with genetic predetermination to clotting disorders may be served well be fitted with the grafts under the anti-thrombotic coatings such as heparin or nitric oxide releasing.

Pediatric and Congenital Applications

1. Conventional flap model is especially useful for children with congenital vascular disorders requiring interviewing grafts. Unlike most of the adult patients, the children need grafts that will be able to grow with the individual as he or she ages. Tissue-engineered vascular grafts (TEVGs), which are scaffolds that will remodel to be a part of the patient's body, are now the best solution in such cases. Such grafts are constructed from patient-derived cells or from decellularized structures that provide signals for tissue self-healing rather than acting as a mesh that requires re-surgery. Although tailored vascular grafts are promising technologies, the following problems are considered to be unsolved. Patient specific grafts are expensive to make, can be technically complex, require infrastructure and specialist skills to make them making them less accessible.

Current management systems should also be enriched with changes to appropriately regulate the production of personalized grafts based on advanced knowledge, without compromising the benefits innovation and effectiveness. Thus, concepts of personalized medicine for vascular grafts are quite novel and are basically solutions which address unique requirements of patients. Due to many improvements in the imaging, bioengineering, and molecular science, personalized graft will lead to better results, fewer side effects, and better quality of life of patients. Looking into the future we can claim that it is personalized vascular grafts that will be the focus of advanced vascular medicine.

2. Greater regulatory nod for the new grafts lays down the importance of clinical success and safety anomalies. Unlike adult patients, children require grafts that can accommodate growth over time. Tissue-engineered vascular grafts (TEVGs), designed to grow and remodel with the patient, are emerging as an ideal solution in these cases. These grafts are created using patient-derived cells or decellularized scaffolds that promote natural tissue regeneration, eliminating the need for repeated surgeries. While personalized vascular grafts offer immense potential, challenges remain in their widespread adoption. The cost and complexity of creating patient-specific grafts, along with the need for sophisticated infrastructure and expertise, limit their accessibility. Regulatory frameworks also need to evolve to address the unique nature of personalized grafts, balancing innovation with safety and efficacy. In conclusion, personalized medicine in vascular grafts represents a paradigm shift, offering solutions that are tailored to the individual needs of patients. By leveraging advances in imaging, bioengineering, and molecular science, personalized grafts promise improved outcomes, reduced complications, and a higher quality of life for patients. As technology continues to evolve, personalized vascular grafts are poised to become a cornerstone of modern vascular medicine.

Regulatory and Clinical Developments

1. Increasing regulatory approvals for novel grafts emphasize clinical efficacy and safety. Technology transfer from the laboratory to clinical practice involves active cooperation among the researchers, clinicians and manufacturers. The design and usage of vascular grafts are still under some very close-established regulations to be able to release quality vascular grafts. Federal agencies and other regional health regulatory bodies that include U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and others analyze vascular grafts through pre-clinical and clinical testing procedures. These valuations are based on biocompatibility, mechanical strength, wear stability and lack of negative response such as thrombosis, infection, graft rejection or poor bonding.

2. A significant development in the Bio-scaffold regulatory framework in recent past is the categorization of tissue-engineered and bioengineered grafts as a separate category that needs a separate set of evaluation criteria. Issue-engineered vascular grafts (TEVGs), designed to grow and remodel with the patient, are emerging as an ideal solution in these cases. These grafts are created using patient-derived cells or decellularized scaffolds that promote natural tissue regeneration, eliminating the need for repeated surgeries.

CONCLUSION

Vascular graft research and development is experiencing a revolutionary period, including optimizing thrombosis, infection, and low patency, especially in small diameter grafts. Achievements in the sphere of bioengineering, advanced materials, as well as smart technologies create the base for the development of the improved grafts with better biocompatibility, durability, and functionality. Decellularized scaffolds with stem cell integration and 3D bioprinting represents an enormous potential for inducing native tissue response and decrease complications. Likewise, drug-eluting and biodegradable grafts are improving clinical results by reducing the problems of restenosis and improving the process of vascular therapeutic. Biosensors and responsive material integration into the graft design result in real-time monitoring and dynamic responsiveness. Fresh technologies have continued to expand the knowledge horizons in the medical field through biosensors in the graft designs. New strategies in vascular graft development are no longer limited to bulk properties but have already shifted through biocompatibility, procurement of individualized graft for particular patients and, integrating with tissue regeneration competence. These enhancement offers great potential in the management of vascular diseases and minimizing complications, allowing probably enhanced and long-lasting graft system in clinic setting.

However, problems like the applicability of bioengineered grafts, the relative cost factor and conclusive clinical confirmation are yet to come. Multi-disciplinary strategic partnership models are an important element in reducing these gaps and help to bring research laboratory innovation to the broad clinical practice. Therefore, the interdisciplinary approach that unites biology, material sciences, and technology is leading to the paradigm shift in the vascular graft's development and use, holding great promise to enhance the efficacy of the treatment for the patient, decrease morbidity, and transform the technique of vascular surgery. The future development of these emerging trends will therefore rely on sustained innovation activity and the integration within other fields. One of the most important factors in both designing and the resultant performance of vascular grafts, would be biocompatibility of the material that will come in contact with the body and cause least reaction from the host. Thus, for the case of vascular grafts, biocompatibility can be understood as dimensions that include the immune reactions, endothelial cells adhesion, thrombosis, and long-term patency. Maximizing biocompatibility is a major concern of current studies and developing in the quest for a vascular graft.

CHALLENGES AND FUTURE DIRECTIONS

However, several problems are still present today. The process frameworks for new grafts especially bioengineered and hybrid forms may take considerable time, and can also be expensive, which may be to the detriment of beneficiaries. Moreover, differences in patient responses and long-term graft performance of the new technologies need more clinical outcome data. In conclusion, high importance should be placed on the regulatory and clinical progress of vascular graft technologies, which plays significant role into the development of effective technologies that ensure their safety. With vascular medicine further expanding through advancements in technology and science, the expanding boundaries of regulation and frameworks, along with stringent clinical tests will serve a huge part in offering life enhancing solutions to global patients.

REFERENCES

1. K. Hu *et al.*, "History, progress and future challenges of artificial blood vessels: A narrative review," *Biomaterials Translational,* vol. 3, no. 1, p. 81, 2022.
2. E. Vahabli *et al.*, "The Technological Advancement to Engineer Next-Generation Stent-Grafts: Design, Material, and Fabrication Techniques," *Advanced healthcare materials,* vol. 11, no. 13, p. 2200271, 2022.
3. G. Zhu, M. Wu, Z. Ding, T. Zou, and L. Wang, "Biological properties of polyurethane: Issues and potential for application in vascular medicine," *European Polymer Journal,* p. 112536, 2023.
4. K. K. Das, R. M. Tiwari, O. Shankar, P. Maiti, and A. K. Dubey, "Tissue-engineered vascular grafts for cardiovascular disease management: current strategies, challenges, and future perspectives," *MedComm–Biomaterials and Applications,* vol. 3, no. 3, p. e88, 2024.
5. S. Matthew *et al.*, "GillesPy2: A Biochemical Modeling Framework for Simulation Driven Biological Discovery," *Letters in biomathematics,* vol. 10, no. 1, p. 87, 2023.
6. Y. Naito *et al.*, "Vascular tissue engineering: towards the next generation vascular grafts," *Advanced drug delivery reviews,* vol. 63, no. 4-5, pp. 312-323, 2011.
7. H. Jouda, L. Larrea Murillo, and T. Wang, "Current progress in vascular engineering and its clinical applications," *Cells,* vol. 11, no. 3, p. 493, 2022.
8. S. Pashneh-Tala, S. MacNeil, and F. Claeyssens, "The tissue-engineered vascular graft—past, present, and future," *Tissue Engineering Part B: Reviews,* vol. 22, no. 1, pp. 68-100, 2016.
9. M. A. Melikulovich, "Use of Biomaterials in Vascular Surgery," *Miasto Przyszłości,* vol. 54, pp. 436-438, 2024.
10. B. Ratner, "Vascular grafts: technology success/technology failure," *BME frontiers,* vol. 4, p. 0003, 2023.
11. P. Gupta and B. B. Mandal, "Tissue-engineered vascular grafts: emerging trends and technologies," *Advanced Functional Materials,* vol. 31, no. 33, p. 2100027, 2021.
12. F. Stefano *et al.*, "Endovascular Management of Juxtarenal and Pararenal Abdominal Aortic Aneurysms: Role of Chimney Technique," *Vascular & Endovascular Review,* vol. 6, 2023.
13. X. Ren *et al.*, "Surface modification and endothelialization of biomaterials as potential scaffolds for vascular tissue engineering applications," *Chemical Society Reviews,* vol. 44, no. 15, pp. 5680-5742, 2015.
14. M. Lele, S. Kapur, S. Hargett, N. M. Sureshbabu, and A. K. Gaharwar, "Global trends in clinical trials involving engineered biomaterials," *Science Advances,* vol. 10, no. 29, p. eabq0997, 2024.
15. T. Pennel and P. Zilla, "Clinical applications and limitations of vascular grafts," *Tissue-Engineered Vascular Grafts,* pp. 3-34, 2020.
16. N. Kutner, K. R. Kunduru, L. Rizik, and S. Farah, "Recent advances for improving functionality, biocompatibility, and longevity of implantable medical devices and deliverable drug delivery systems," *Advanced Functional Materials,* vol. 31, no. 44, p. 2010929, 2021.
17. A. Aggarwal, C. S. Jenkins, J. Mangla, C. J. Shanley, and G. W. Long, "Innovations in vascular device surface engineering: a clinical review," *Surface Innovations,* vol. 2, no. 1, pp. 3-16, 2014.
18. N. A. Jarad, A. Chami, J. I. Weitz, and T. F. Didar, "Advancements in surface modification strategies of vascular grafts to improve biocompatibility and tissue integration," *Exploration of BioMat-X,* vol. 1, no. 5, pp. 241-265, 2024.
19. M. C. Spataru, M. S. Baltatu, A. V. Sandu, and P. Vizureanu, "General Trends on Biomaterials Applications: Advantages and Limitations," 2024.
20. J. Choi, E. J. Lee, W. B. Jang, and S.-M. Kwon, "Development of Biocompatible 3D-Printed Artificial Blood Vessels through Multidimensional Approaches," *Journal of Functional Biomaterials,* vol. 14, no. 10, p. 497, 2023.
21. A. Bandyopadhyay, I. Mitra, S. B. Goodman, M. Kumar, and S. Bose, "Improving biocompatibility for next generation of metallic implants," *Progress in materials science,* vol. 133, p. 101053, 2023.
22. M. Z. Al Mahmud, "Exploring the versatile applications of biocomposites in the medical field," *Bioprinting,* vol. 36, p. e00319, 2023.
23. D. Suhag, "Biomaterials for Cardiovascular Applications," in *Handbook of Biomaterials for Medical Applications, Volume 2: Applications*: Springer, 2024, pp. 105-139.
24. C. Blume *et al.*, "Vascular implants–new aspects for in situ tissue engineering," *Engineering in life sciences,* vol. 22, no. 3-4, pp. 344-360, 2022.
25. V. A. Georgeanu, O. Gingu, I. V. Antoniac, and H. O. Manolea, "Current options and future perspectives on bone graft and biomaterials substitutes for bone repair, from clinical needs to advanced biomaterials research," *Applied Sciences,* vol. 13, no. 14, p. 8471, 2023.
26. M. N. Helmus, D. F. Gibbons, and D. Cebon, "Biocompatibility: meeting a key functional requirement of next-generation medical devices," *Toxicologic pathology,* vol. 36, no. 1, pp. 70-80, 2008.